ReviewCardiology journal2022
Continuous-flow left ventricular assist device: Current knowledge, complications, and future directions.
Review in Cardiology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cardiovascular Physiology During Mechanical Circulatory Support: Implications for Management and Monitoring.Journal of clinical medicine · 2025Review
- Increased neutrophil extracellular trap formation in left ventricular assist device driveline infections: an initial report.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- The Pivotal Role of an Early Post-Acute Cardiac Rehabilitation as an Evidence-Based Management of Left Ventricular Assist Device Patients.Artificial organs · 2025Observational
- In Vitro and In Silico Characterization of the Aggregation of Thrombi on Textured Ventricular Cannula.Annals of biomedical engineering · 2024Article
- Current status and future directions in pediatric ventricular assist device.Heart failure reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term continuous-flow left ventricular assist devices have become a real alternative to heart transplantation in patients with advanced heart failure, achieving a promising 2-year event-free survival rate with new-generation devices. Currently, this technology has spread throughout the world, and any cardiologist or cardiac surgeon should be familiar with its fundamentals and its possible complications as well as the advances made in recent years. The aim of this review is to describe current knowledge, management of complications, and future directions of this novel heart-failure therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.